Upload Avatar (500 x 500)
Xin Wang
wangx@xmu.edu.cn
English, Chinese
Fujian
Xiamen University
Medical
  • 2009-2013 PhD in Biomedical Sciences: Sanford-Burnham Medical Research Institute
  • 2005-2008 Master's in Pharmacology: Shanghai Jiao Tong University
  • 2001-2005 Bachelor's in Pharmacy: Chongqing Medical University
  • 2015-present - Xiamen University - Professor
  • 2014-2015 - Sanford-Burnham Medical Research Institute - Postdoctoral Researcher
  • 2013-2014 - University of California, San Diego (UCSD) - Postdoctoral Researcher
  • 2013-2013 - Sanford-Burnham Medical Research Institute - Postdoctoral Researcher
  • 2008-2009 - Sanford-Burnham Medical Research Institute - Visiting Scholar
  • 2023: National Science Fund for Distinguished Young Scholars
  • 2023: 17th Fujian Youth Science and Technology Award
  • 2018: Xiamen Science and Technology Progress First Prize
  • 2018: Xiamen Outstanding Young Talent
  • 2018: National Science Fund for Excellent Young Scholars
  • 2017: Fujian High-Level Innovative Talent Plan Expert
  • 2017: Fujian Distinguished Young Scholar Fund
  • 2016: Minjiang Scholar Distinguished Professor
  • 2016: National High-Level Young Talent
  • 2010: Young Scholar Award of Alzheimer's Association
Molecular mechanisms of cognitive disorders
Drug targets for cognitive disorders
  • β2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function., Gao Y, Hong Y, Huang L, Zheng S, Zhang H, Wang S, Yao Y, Zhao Y, Zhu L, Xu Q, Chai X, Zeng Y, Zeng Y, Zheng L, Zhou Y, Luo H, Zhang X, Zhang H, Zhou Y, Fu G, Sun H, Huang TY, Zheng Q, Xu H, Wang X*., 2023
  • β2-microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice., Zhao Y, Zheng Q, Hong Y, Gao Y, Hu J, Lang M, Zhang H, Zhou Y, Luo H, Zhang X, Sun H, Yan XX, Huang TY, Wang YJ, Xu H, Liu C, Wang X*., 2023
  • Metabolic reprogramming in astrocytes results in neuronal dysfunction in intellectual disability., Zhang H#, Zheng Q#, Guo T#, Zhang S#, Zheng S, Wang R, Deng Q, Yang G, Zhang S, Tang L, Qi Q, Zhu L, Zhang X-F, Luo H, Zhang X, Sun H, Gao Y, Zhang H, Zhou Y, Han A, Zhang C-S, Xu H, Wang X*., 2022
  • USP25 inhibition ameliorates Alzheimer’s pathology through regulating APP processing and Aβ generation., Zheng Q#, Song B#, Li G#, Cai F#, Wu M, Zhao Y, Jiang L, Guo T, Shen M, Hou H, Zhou Y, Zhao Y, Di A, Zhang L, Zeng F, Zhang X-F, Luo H, Zhang X, Zhang H, Zeng Z, Huang T, Dong C, Qing H, Zhang Y, Zhang Q, Wang X, Wu Y, Xu H*, Song W*, and Wang X*., 2022
  • SNX14 deficiency-induced defective axonal mitochondrial transport in Purkinje cells underlies cerebellar ataxia and can be reversed by valproate., Zhang H#, Hong Y#, Yang W, Wang R, Yao T, Wang J, Liu K, Yuan H, Xu C, Zhou Y, Li G, Zhang L, Luo H, Zhang X, Du D, Sun H, Zheng Q, Zhang Y-W, Zhao Y, Zhou Y, Xu H, Wang X*., 2021
  • Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer’s brains is mediated by USP25., Zheng Q#, Li G#, Wang S, Zhou Y, Liu K, Gao Y, Zhou Y, Zheng L, Zhu L, Deng Q, Wu M, Di A, Zhang L, Zhao Y, Zhang H, Sun H, Dong C, Xu H, Wang X*., 2021
  • The deubiquitinase USP6 affects memory and synaptic plasticity through modulating NMDA receptor stability., Zeng F#, Ma X#, Zhu L#, Xu Q, Zeng Y, Gao Y, Li G, Guo T, Zhang H, Tang X, Wang Z, Ye Z, Zheng L, Zhang H, Zheng Q, Li K, Lu J, Qi X, Luo H, Zhang X, Wang Z, Zhou Y, Yao Y, Ke R, Zhou Y, Liu Y, Sun H, Huang T, Shao Z, Xu H, and Wang X*., 2019
  • Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction via modulation of glutamate receptor recycling in Down's syndrome., Wang X, Zhao Y, Zhang X, Badie H, Zhou Y, Mu Y, Loo LS, Cai L, Thompson RC, Yang B, Chen Y, Johnson PF, Wu C, Bu G, Mobley WC, Zhang D, Gage FH, Ranscht B, Zhang YW, Lipton SA, Hong W, Xu H*., 2013
Cognitive Disorders Molecular Mechanisms Drug Targets Alzheimer'S Disease Down Syndrome Synaptic Function Neurodegeneration Gene Modification Electrophysiology Pharmacology

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.